Table 1. Key patient characteristics, RO... | American Society of Hematology

Table 1.

Key patient characteristics, RO data, drug half-life, and treatment responses

	Sex	Age, y	Disease status	Stage	NIV dose, mg/kg	Baseline PD-1 on T cells, %	Peak RO, %	Trough RO, %	NIV40 half-life, h	FDG-PET DS	Further therapy	Clinical status at follow-up	Follow-up, mo
1	M	31	Rel	IVB	0.5	—	—	—	203.0	1	No SCT	Relapse	20
2	M	58	PP	IVB	0.6	—	—	—	—	X	SCT	Remission	16
3	F	21	Rel	IIA	0.7	9.1	95.6	98.9	—	1	SCT	Remission	4
4	M	34	PP	IIIA	0.4	10	100	100	249.9	1	No SCT	Remission	17
5	M	23	Rel	IVBE	0.8	13.5	100	100	—	1	SCT	Remission	23
6	M	36	Rel	IVB	0.4	45.6	97.1	100	—	3	SCT	Remission	22
7	F	18	PP	IIIS	0.5	5.3	100	100	337.7	1	SCT	Remission	21
8	M	40	PP	II	0.7	1.7	100	100	—	2	SCT	Remission	16
9	M	21	PP	IVBE	0.6	16.6	100	100	—	2	SCT	Relapse	19
10	M	21	Rel	IVB	0.7	19.2	100	100	—	X	SCT	Remission	19
11	M	29	Rel	IIIB	0.7	30.7	98.4	45.3	—	NA∗	Chemo->SCT	Remission	18
12	F	38	PP	IIIB	0.8	10.1	98.1	100	115.9	3	SCT	Remission	16
13	M	24	Rel	IVBE	0.7	17	100	100	221.6	4	Chemo->SCT	Remission	14
14	M	18	R/R	IIIS	0.7	5.4	100	—	—	4	Allo-SCT	Remission	14
15	M	22	Rel	IIA	0.7	—	—	—	208.8	3	SCT	Remission	11
16	M	24	Rel	IVB	0.7	20.8	96.6	100	205.7	5a	Chemo->SCT	Remission	12
17	M	34	PP	IIA	0.7	18.1	99.5	100	—	4	Chemo->SCT	Remission	10
18	M	66	PP	IVBE	0.6	1.7	94.1	0.1	148.5	4	No SCT	Remission	11
19	M	62	Rel	IIA	0.7	10.8	98.1	100	121.6	4	No SCT	Relapse	11
20	M	39	Rel	IIIA	0.7	18.4	99.4	100	147.4	4	SCT	Remission	10

	Sex	Age, y	Disease status	Stage	NIV dose, mg/kg	Baseline PD-1 on T cells, %	Peak RO, %	Trough RO, %	NIV40 half-life, h	FDG-PET DS	Further therapy	Clinical status at follow-up	Follow-up, mo
1	M	31	Rel	IVB	0.5	—	—	—	203.0	1	No SCT	Relapse	20
2	M	58	PP	IVB	0.6	—	—	—	—	X	SCT	Remission	16
3	F	21	Rel	IIA	0.7	9.1	95.6	98.9	—	1	SCT	Remission	4
4	M	34	PP	IIIA	0.4	10	100	100	249.9	1	No SCT	Remission	17
5	M	23	Rel	IVBE	0.8	13.5	100	100	—	1	SCT	Remission	23
6	M	36	Rel	IVB	0.4	45.6	97.1	100	—	3	SCT	Remission	22
7	F	18	PP	IIIS	0.5	5.3	100	100	337.7	1	SCT	Remission	21
8	M	40	PP	II	0.7	1.7	100	100	—	2	SCT	Remission	16
9	M	21	PP	IVBE	0.6	16.6	100	100	—	2	SCT	Relapse	19
10	M	21	Rel	IVB	0.7	19.2	100	100	—	X	SCT	Remission	19
11	M	29	Rel	IIIB	0.7	30.7	98.4	45.3	—	NA∗	Chemo->SCT	Remission	18
12	F	38	PP	IIIB	0.8	10.1	98.1	100	115.9	3	SCT	Remission	16
13	M	24	Rel	IVBE	0.7	17	100	100	221.6	4	Chemo->SCT	Remission	14
14	M	18	R/R	IIIS	0.7	5.4	100	—	—	4	Allo-SCT	Remission	14
15	M	22	Rel	IIA	0.7	—	—	—	208.8	3	SCT	Remission	11
16	M	24	Rel	IVB	0.7	20.8	96.6	100	205.7	5a	Chemo->SCT	Remission	12
17	M	34	PP	IIA	0.7	18.1	99.5	100	—	4	Chemo->SCT	Remission	10
18	M	66	PP	IVBE	0.6	1.7	94.1	0.1	148.5	4	No SCT	Remission	11
19	M	62	Rel	IIA	0.7	10.8	98.1	100	121.6	4	No SCT	Relapse	11
20	M	39	Rel	IIIA	0.7	18.4	99.4	100	147.4	4	SCT	Remission	10

NA, not applicable; SCT, stem cell transplant; X, Deauville score X.

Discontinued study protocol in view of grade 2 iRAE.